Treatment regimen in recurrent high-grade malignant non-Hodgkin's lymphomas;Rezidivtherapie hochmaligner Non-Hodgkin-Lymphome

Internist

Volumn 38, Issue 2, 1997, Pages 143-149

  Schmitz, N ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; IDARUBICIN; IFOSFAMIDE; MELPHALAN; MESNA; METHOTREXATE; METHYLPREDNISOLONE; MITOGUAZONE; MITOXANTRONE; MONOCLONAL ANTIBODY; PACLITAXEL; PREDNISONE; PROCARBAZINE;

HUMAN; NONHODGKIN LYMPHOMA; PROGNOSIS; REVIEW; STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HUMANS; LYMPHOMA, HIGH-GRADE; LYMPHOMA, NON-HODGKIN; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; SURVIVAL RATE;

EID: 0031048683     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Amlot PL, Stone MJ, Cunningham D, Fay J, Newman J, Collins R, May R, McCarthy M, Richardson J, Ghetie V, Ramilo O, Thorpe PE, Uhr JW, Vitetta ES (1993) A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 82:2624-2633
2. Armitage JO (1993) Treatment of Non-Hodgkin's lymphoma. N Engl J Med 328:1023-1030
3. Barrett AJ, Malkovska V (1996) Graft-versus- leukaemia: Understanding and using the alloimmune response to treat haematological malignancies. Br J Haematol 93:754-761
4. Cabanillas F, Hagemeister FB, Bodey GP, Freireich EJ (1992) IMVP 16: An effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 60:693-697
5. Cabanillas F, Hagemeister FB, McLaughlin P, Velasquez WS, Riggs S, Fuller L, Smith T (1987) Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 5:407-412
6. Chao NJ, Kastrissios H, Long GD, Negrin RS, Horning SJ, Wong RM, Blaschke TF, Blume KG (1995) A new preparatory regimen for autologous bone marrow transplantation for patients with lymphoma. Cancer 75:1354-1359
7. Chao NJ, Rosenberg SA, Horning SJ (1990) CEPP(B): An effective and well-tolerated regimen is poor-risk, aggressive non-Hodgkin's lymphoma. Blood 76:1293-1298
8. Chopra R, Goldstone AH, Pearce R, Philip T, Petersen F, Appelbaum F, De Vol E, Ernst P (1992) Autologous versus allogeneic bone marrow transplantation for Non-Hodgkin' lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry Data. J Clin Oncol 10:1690-1695
9. Fielding AK, Pearce RM, Jaghipour G, Linch DC, Philip T, Carella A, Colombat P, Fouillard L, Schmitz N, Lister A, Hartmann O, Verdonck L, Goldstone AH (1996) Autologous transplantation for lymphoma - trends over 15 years from 3750 cases reported to the EBMT lymphoma registry. What have we learned? J Clin Oncol (In Press)
10. Gisselbrecht Ch, Maraninchi D, Rico JL, Milpied N, Coiffier B, Divine M, Tiberghien P, Bosly A, Tilly H, Boulat O, Brandely M (1994) Interleukin-2 treatment in lymphoma: a phase II multicenter study. Blood 83:2081-2085
11. Goss P, Shepherd F, Scott G, Baker M, Sutton D, Sutcliffe S (1995) DICE (dexamethasone, ifosfamide, cisplatin, etoposide) as salvage therapy in Non-Hodgkin's lymphomas. Leukemia & Lymphoma 18:123-129
12. Gratwohl A, Hermans J, Baldemero H, for the European Group for Blood and Marrow Transplantation (EBMT) (1995) Blood and Marrow Transplantation in Europe 1995. Bone Marrow Transplant (In Press)
13. Grossbard M, Gribben JG, Freedman AS, Lambert JM, Kinsella J, Rabinowe SN, Eliseo L, Taylor JA, Blättler WA, Epstein CL, Nadler LM (1993) Adjuvant immunotoxin therapy with anti-B4- blocked ricin after autologous bone marrow transplantation for patients with B-cell non- Hodgkin's lymphoma. Blood 81:2263-2271
14. Ho AD, Del Valle F, Rückle H, Schwammborn J, Schlimok G, Hiddemann W, Meusers P, Thiel E, Dörken B, Hunstein W (1989) Mitoxantrone and high-dose cytarabine as salvage therapy for refractory non-Hodgkin's lymphoma. Cancer 64:1388-1392
15. Jagannath S, Dicke KA, Armitage JO, Cabanillas FF, Horwitz LJ, Vellekoop L, Zander AR, Spitzer G (1986) High-dose cyclophosphamide, carmustine, and etoposid and autologous bone marrow transplantation for relapsed Hodgkin's disease. Ann Int Med 104:163-168
16. Jones RJ, Ambinder RF, Piantadosi St, Santos GW (1991) Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 77:649-653
17. Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, Estes J, Tuck M, Regan D, Fisher S, Glenn StD, Wahl RL (1996) Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 14:1974-1981
18. Klumpp TR, Mangan KF, Glenn LD, Malaspina DR, Cropper T, Mullaney M, Macdonald JS (1993) Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non- Hodgkin's lymphoma. Bone Marrow Transplant 12:337-345
19. Meyer RM, Hryniuk WM, Goodyear MDE (1991) The role of dose intensity in determining outcome in intermediate-grade non- Hodgkin's lymphoma. J Clin Oncol 9:339-347
20. Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH (1995) BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory Non- Hodgkin's lymphoma. J Clin Oncol 13:588-595
21. Mills W, Strang J, Goldstone AH, Linch DC (1995) Dose intensification of etoposide in the BEAM ABMT protocol for malignant lymphoma. Leuk Lymph 17:263-270
22. Pfreundschuh MG, Rueffer U, Lathan B, Schmitz N, Brosteanu O, Hasenclever D, Haas R, Kirchner H, Koch P, Kuse R, Loeffler M, Diehl V, for the German Hodgkin's Disease Study Group (1994) DEXA- BEAM in patients with Hodgkin's disease refractory to multi-drug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group. J Clin Oncol 12:580-586
23. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht Ch, Cahn J-Y, Harousseau J-L, Coiffier B, Biron P, Mandelli F, Chauvin F (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-hodgkin's lymphoma. N Engl J Med 333:1540-1545
24. Philip Th, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY, Colombat Ph, Goldstone AH, Gorin NC, Flesh M, Laporte JP, Maraninchi M, Pico J, Bosly A, Anderson C, Schots R, Biron P, Cabanillas F, Dicke K (1987) High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non- Hodgkin's lymphoma. N Engl J Med 316:1493-1498
25. Przepiorka D, Nath R, Ippoliti C, Mehra R, Hagemeister F, Diener K, Dimopoulos M, Giralt S, Khouri I, Samuels B, van Biesen K, Andersson B, Deisseroth AB, Luna M, Cabanillas F, Champlin R (1995) A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma. Leuk Lymph 17:427-433
26. Ratanatharathorn V, Uberti J, Karanes Ch, Abella E, Lum AL, Momin F, Cummings G, Sensenbrenner LL (1994) Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with Non-Hodgkin's lymphoma. Blood 84:1050-1055
27. Rodriguez MA, Cabanillas FC, Velasquez W, Hagemeister FB, McLaughlin P, Swan F, Romaguera JE (1995) Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol 13:1734-1741
28. Schenkein DP, Dixon P, Desforges JF, Berkman E, Erban JK, Ascensao J, Miller KB (1994) Phase I/II study of cyclophosphamide, carboplatin, and etoposide and autologous hematopoietic stem-cell transplantation with posttransplant interferon alfa-2b for patients with lymphoma and Hodgkin's disease. J Clin Oncol 12:2423-2431
29. Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, Demuynck HMS, Link H, Zander A, Barge A, Borkett K (1996) Randomised trial of filgrastin-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 347:353-357
30. Smith TJ, Hillner BE, Schmitz N, Linch DC, Dreger P, Goldstone DH, Boogaerts MA, Ferrant A, Link H, Zander A, Yanovich S, Kitchin R, Erder MH (1996) Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral blood progenitor cell transplantation and autologous bone marrow transplantation in patients with Hodgkin and Non- Hodgkin lymphoma. J Clin Oncol (In Press)
31. Snyder MJ, Johnson DB, Daly MB, Giguere JK, Harman GH, Harden EA, Johnson RA, Leff RS, Mercier RJ, Messerschmidt GL, Rubinsak JR, Essell JH, Halvorson RD, Thompson JM (1994) Carmustine, ara C, cyclophosphamide and etoposide with autologous bone marrow transplantation in relapsed or refractory lymphoma: a dose-finding study. Bone Marrow Transplant 14:595-600
32. Sparano JA, Wiernik PH, Leaf A, Dutcher JP (1993) Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: evidence for a schedule-dependent effect favoring infusional administration of chemotherapy. J Clin Oncol 11:1071-1079
33. Vaughan WP, Kris E, Vose J, Bierman PhJ, Gwilt P, Armitage JO (1995) Phase I/II study incorporating intravenous hydroxyurea into high-dose chemotherapy for patients with primary refractory or relapsed and refractory intermediate-grade and high-grade malignant lymphoma. J Clin Oncol 13:1089-1095
34. Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, Jagannath S, Hagemeister FB, Redman JR, Swan F, Barlogie B (1988) Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 71:117-122
35. Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, Romaguera J, Rubenstein E, Cabanillas F (1994) ESHAP - an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 12:1169-1176
36. Weaver ChH, Petersen FB, Appelbaum FR, Bensinger WI, Press O, Martin P, Sandmaier B, Deeg HJ, Hansen JA, Brunvand M, Rowley S, Benyunes K, Chauncey Th, Fefer A, Hackman R, Gooley T, Schiffmann K, Storb R, Sullivan KM, Weiden P Witherspoon R, Buckner CD (1994) High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma. J Clin Oncol 12:2559-2566
37. Wheeler C, Antin JH, Churchill WH, Come SE, Smith BR, Bubley GJ, Rosenthal DS, Rappaport JM, Ault KA, Schnipper LE, Edet JP (1990) Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: A dose-finding study. J Clin Oncol 8:648-656
38. White CA, Halpern SE, Parker BA, Miller RA, Hupf HB, Shawler DL, Collins HA, Royston I (1996) Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti-idotype monoclonal antibodies. Blood 87:3640-3649
39. Wilson WH, Bryant G, Bates S, Fojo A, Wittes RE, Steinberg SM, Kohler DR, Jaffe ES, Herdt J, Cheson BD, Chabner BA (1993) EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory Non-Hodgkin's lymphoma. J Clin Oncol 11:1573-1582
40. Wilson WH, Jain V, Bryant G, Cowan KH, Carter Ch, Cottler-Fox M, Goldspiel B, Steinberg SM, Longo DL, Wittes RE (1992) Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors. J Clin Oncol 10:1712-1722
41. Younes A, Sarris A, Melnyk A, Romaguera J, McLaughlin P, Swan F, Rodriguez MA, Hagemeister F, Moore D, North L, Smith TL, Cabanillas F (1995) Three-hour paclitaxel infusion in patients with refractory and relapsed Non-Hodgkin's lymphoma. J Clin Oncol 13:583-587
42. Zeis M, Uharek L, Glass B, Steinmann J, Dreger P, Gassmann W, Schmitz N (1996) Allogeneic MHC-mismatched activated natural killer cells administered after bone marrow transplantation provide a strong graft- versus-leukaemia (GVL) effect in mice. Br J Haematol (In Press)